Related references
Note: Only part of the references are listed.Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S. Hong et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life
Alexander Drilon
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
James H. Suh et al.
ONCOLOGIST (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Russell W. Jenkins et al.
CLINICAL LUNG CANCER (2015)
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F. Farago et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
MET Mutation Associated with Responsiveness to Crizotinib
Saiama N. Waqar et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Impact of Genomic Changes on Treatment of Lung Cancer
Stephanie Cardarella et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Implementing personalized cancer genomics in clinical trials
Richard Simon et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
Yoshiyuki Suehara et al.
CLINICAL CANCER RESEARCH (2012)
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer
Rui Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Hiroyuki Yasuda et al.
LANCET ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The $1,000 genome, the $100,000 analysis?
Elaine R. Mardis
GENOME MEDICINE (2010)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Share Paper
